David Onions, PhD, has been promoted to the newly created position of chief medical officer of Invitrogen (Carlsbad, California). Onions joined Invitrogen in 2003. He was a founder and director of Q-One Biotech – which was acquired by Invitrogen through its purchase of BioReliance – where he served as BioReliance’s chief scientific officer. Onions also holds a chair in veterinary molecular virology at the University of Glasgow. Invitrogen provides life science technologies for disease research, drug discovery and commercial bioproduction. Its own R&D efforts are focused on various areas of biological discovery, including functional genomics, proteomics, bioinformatics and cell biology.

Dr. David Weissberg was appointed CEO of Molecular Diagnostics (Chicago), replacing Denis O’Donnell, MD, who voluntarily stepped down as a director, president and CEO as part of a company restructuring. Weissberg has helped to build several medical practice and service-related businesses and is a major investor in Molecular Diagnostics. Molecular Diagnostics develops cancer-screening systems, which can be used in a laboratory or at the point of care.

No Comments